Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials

Wang, Yong; Shi, Yonghong; Xu, Zhen; Fu, Huan; Zeng, Huiqing; 鄭, 国慶

doi:10.1016/j.jpsychires.2019.07.003

Cited by 40 publications

(32 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PCI is highly advantageous for patients with CHD, PPCP remains a main challenge. Chinese herbs have shown their signi cant therapeutic effects for patients with CHD and depression [24,25].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Yinxing Mihuan oral solution in the treatment of patients with post-PCI chest pain: A multicenter, prospective, randomized, double-blind, placebo-controlled study

et al. 2021

Preprint

View full text Add to dashboard Cite

Background：Coronary artery disease (CHD) now accounts for approximately one third of all deaths globally and up to one-quarter of patients may have either continues or recurrent post-PCI chest pain. Yinxing Mihuan oral solution (YMOS) has been proven to bring clinical benefits for patients with CHD and Ginkgo biloba extract can relieve depression in mice. No high-quality randomized controlled trials on YMOS have been published. The aim of this study is to evaluate the efficacy and safety of Yinxing Mihuan oral solution (YMOS) in the treatment of patients with post-percutaneous coronary intervention (PCI) chest pain. This study also aimed to relieve the symptoms of chest pain as a primary outcome, improve the anxiety as a secondary outcome, assess therapeutic effects of YMOS on chest pain, and explore its effects on chest pain caused by psychological disorders after PCI.Methods: 320 patients with symptoms related to heart and a confirmed history of PCI for coronary heart disease (CHD) without the need to undergo selective coronary revascularization plan were recruited in this randomized controlled trial. The included participants were randomly assigned (at a ratio of 1:1) to experimental group and control group; patients in the experimental group received YMOS and standardized medical treatment, while those in control received placebo (10 ml) for three times/day for 12 weeks and standardized medical treatment regimen. The endpoints of the study included Seattle angina questionnaire (SAQ) score, Hamilton anxiety rating scale (HAMA), Hamilton rating scale for depression (HRSD), Canadian Cardiovascular Society (CCS) angina score, New York Heart Association (NYHA) classification, visual analogue scale (VAS), 12-Item short form survey (SF-12), frequency of angina-related symptoms per week, nitroglycerin discontinuation, and reduction rate of HAMA score.Discussion: This clinical trial can provide reliable evidence regarding the efficacy and safety of YMOS for patients with post-PCI chest pain.Trial registration: This research has been registered at the Chinese Clinical Trial Registry (Registration No. ChiCTR2000028760) on January 1, 2020. http://www.chictr.org.cn/showproj.aspx?proj=47528

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Yinxing Mihuan oral solution in the treatment of patients with post-PCI chest pain: A multicenter, prospective, randomized, double-blind, placebo-controlled study

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, almost all meta-analyses reported the low quality of the included RCTs, identifying problems in randomization, concealment of allocation, blinding, dropouts, heterogeneity, and sample size. From the above, the meta-analysis conducted by Wang et al 2019included RCTs whose methodological quality was classified as moderate, providing evidence to a certain extent for Chinese herbal medicine's routine use for depression [42]. In addition, in the study conducted by Shi et al (2019), despite the clinical heterogeneity, the authors found that when comparing Chinese herbal medicine with a placebo, the overall quality of evidence according to the primary outcome measures was moderate or high, and the overall quality of evidence in Chinese herbal medicine relative to Western medicine was low or moderate.…”

Section: Chinese Herbal Medicine Tendencies In Research and Clinical mentioning

confidence: 99%

“…The diversity of pathologies covered by the remaining articles is considerable, with three articles related to cancer (involving 54, 14 and 18 RCTs)[33][34][35], three related to hypertension (involving 30, 17 and 39 RCTs)[36][37][38], three related to COVID-19 (involving 19, 7 and 18 RCTs)[39][40][41], two related to depression (involving 40 and 16 RCTs)[42,43], two related to headache (involving 31 and 30 RCTs)[44,45], and the others related to allergic rhinitis (involving 17 RCTs)[46], spinal cord injury (involving 26 RCTs)…”

mentioning

confidence: 99%

Understanding Traditional Chinese Medicine Therapeutics: An Overview of the Basics and Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) is a systematic healthcare system developed from clinical experience based on a scientific model of regulation. TCM relies on unique theories and practices to treat diseases and enhance health. These practices include Chinese herbal medicine and dietetics, acupuncture and moxibustion, and other non-medication therapies such as Chinese bodywork or manual therapy, known as “Tuina”, and traditional biofeedback exercises, known as “Qigong” and “Taijiquan”. The integration of TCM in Western health systems and research requires a rational communicable theory, scientific proof of efficacy and safety, and quality control measures. Understanding the structural concepts of the TCM language makes possible the parallelism to Western physiology, and the inherent rational use of the reflex therapeutic systems, anti-inflammatory mechanisms and mental training involved, for example, in acupuncture and “Qigong”. The results of TCM clinical trials and fundamental research on its nature and mechanisms have encouraged the development and application of well-designed research strategies such as double blinding in acupucture to overcome limitations and resistances in integrating these practices into the existing biomedical paradigms of the West. This review aims to overview some TCM theoretical concepts and the evidence-based clinical application of TCM’s leading practices to create an easy-to-consult and condensed source of information, available for the healthcare community, facilitating the understanding and communication between conventional health professionals and TCM practitioners and acupuncturists.

show abstract

“…Meanwhile, Chinese researchers are making a growing contribution to the neuroscience community. A number of reviews and commentaries have described achievements and challenges in mental health in China from different perspectives (Liu et al, 2011 ; Que, Lu, & Shi, 2019 ; Shi, 2019 ; Wang et al, 2019 a , b , c , d ). Yet, this review aims to provide an overall depiction of psychiatric research and healthcare system in China in the last three decades.…”

Section: Introductionmentioning

confidence: 99%

Psychiatric disorders in China: strengths and challenges of contemporary research and clinical services

Chang

Gong

et al. 2021

Psychol. Med.

View full text Add to dashboard Cite

China accounts for 17% of the global disease burden attributable to mental, neurological and substance use disorders. As a country undergoing profound societal change, China faces growing challenges to reduce the disease burden caused by psychiatric disorders. In this review, we aim to present an overview of progress in neuroscience research and clinical services for psychiatric disorders in China during the past three decades, analysing contributing factors and potential challenges to the field development. We first review studies in the epidemiological, genetic and neuroimaging fields as examples to illustrate a growing contribution of studies from China to the neuroscience research. Next, we introduce large-scale, open-access imaging genetic cohorts and recently initiated brain banks in China as platforms to study healthy brain functions and brain disorders. Then, we show progress in clinical services, including an integration of hospital and community-based healthcare systems and early intervention schemes. We finally discuss opportunities and existing challenges: achievements in research and clinical services are indispensable to the growing funding investment and continued engagement in international collaborations. The unique aspect of traditional Chinese medicine may provide insights to develop a novel treatment for psychiatric disorders. Yet obstacles still remain to promote research quality and to provide ubiquitous clinical services to vulnerable populations. Taken together, we expect to see a sustained advancement in psychiatric research and healthcare system in China. These achievements will contribute to the global efforts to realize good physical, mental and social well-being for all individuals.

show abstract

Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials

Cited by 40 publications

References 50 publications

Efficacy and safety of Yinxing Mihuan oral solution in the treatment of patients with post-PCI chest pain: A multicenter, prospective, randomized, double-blind, placebo-controlled study

Efficacy and safety of Yinxing Mihuan oral solution in the treatment of patients with post-PCI chest pain: A multicenter, prospective, randomized, double-blind, placebo-controlled study

Understanding Traditional Chinese Medicine Therapeutics: An Overview of the Basics and Clinical Applications

Psychiatric disorders in China: strengths and challenges of contemporary research and clinical services

Contact Info

Product

Resources

About